


BAR CODE LABEL 		PCT/US 92/10587 U.S. PATENT APPLICATION <i>11 Dec. 1992</i>			
SERIAL NUMBER 07/809,791		FILING DATE 12/18/91	CLASS 424	GROUP ART UNIT 1502	
APPLICANT	MARTIN J. OLIVER, LOUGHBOROUGH, GREAT BRITAIN; ROBERT A. MORIS, LINO LAKES, MN.				
	CONTINUING DATA*** VERIFIED				
	FOREIGN/PCT APPLICATIONS*** VERIFIED				
<div style="border: 2px solid black; padding: 5px; display: inline-block;"> REC'D 26 JAN 1993 WIPO PCT </div>					
<div style="border: 2px solid black; padding: 5px; display: inline-block; font-weight: bold; font-size: 1.2em;"> PRIORITY DOCUMENT </div>					
FOREIGN FILING LICENSE GRANTED 02/25/92					
STATE OR COUNTRY GB3	SHEETS DRAWING 0	TOTAL CLAIMS 14	INDEPENDENT CLAIMS 1	FILING FEE RECEIVED \$ 820.00	ATTORNEY DOCKET NO. 47982USA9A
ADDRESS	3M OFFICE OF INTELLECTUAL PROPERTY COUNSEL P.O. BOX 33427 ST. PAUL, MN 55133-3427				
TITLE	ALBUTEROL SULFATE SUSPENSION AEROSOL FORMULATIONS				
This is to certify that annexed hereto is a true copy from the records of the United States Patent and Trademark Office of the application as filed which is identified above.					
By authority of the COMMISSIONER OF PATENTS AND TRADEMARKS					
Date DEC 29 1992		Certifying Officer <i>N. Williams</i>			

PATENT APPLICATION SERIAL NO. 077809791

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
FEE RECORD SHEET

080 KP 12/27/91 07809791

1 101 690.00 CX 47982USA9A

PTO-1556
(5/87)



690. CD-101 A

7809791

-1-

DOCKET NUMBER: 47982USA9A

ALBUTEROL SULFATE SUSPENSION AEROSOL FORMULATIONS

5

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

This invention relates to suspension aerosol formulations suitable for the administration of medicaments. In another aspect, it relates to pharmaceutical suspension aerosol formulations containing albuterol sulfate and in yet another aspect to aerosol formulations using 1,1,1,2,3,3,3-heptafluoropropane as the propellant.

15

DESCRIPTION OF THE RELATED ART

Albuterol sulfate is a relatively selective beta-2 adrenergic bronchodilator. It is available in a variety of dosage forms including tablets, syrups and formulations suitable for inhalation. For example, VENTOLIN™ Inhalation Aerosol (commercially available from Allen & Hansburys, Division of Glaxo Inc.; Research Triangle Park, NC) is a metered-dose aerosol unit containing a microcrystalline suspension of albuterol (free base) in propellant (a mixture of trichloromonofluoromethane and dichlorodifluoromethane) with oleic acid. VENTOLIN ROTOCAPS™ for Inhalation (commercially available from Allen & Hansburys) contain a mixture of microfine albuterol sulfate with lactose and are intended for use with a specially designed device for inhaling powder. VENTOLIN™ Solution for Inhalation (commercially available from Allen & Hansburys) is an aqueous solution of albuterol sulfate intended for use with a nebulizer.

35

Chlorofluorocarbons, including trichloromonofluoromethane and dichlorodifluoromethane, have been implicated in the destruction of the ozone layer and their production is being phased out. Hydrofluorocarbon 227 (1,1,1,2,3,3,3-heptafluoropropane) is viewed as being less destructive to ozone than many

chlorofluorocarbon propellants; furthermore, it has a low toxicity and a vapor pressure suitable for use in aerosols.

Patent Applications WO 91/11495 and WO 91/11496 (both to Weir) describe pharmaceutical suspension aerosol formulations comprising a medicinal agent, optionally a surfactant, and a propellant mixture containing a partially fluorinated lower alkane. The patent application specifically discloses an aerosol formulation containing (indicated in percentage by weight) 0.3% salbutamol, 0.2% Span 85, 20.0% pentane, 30.0% 1,1,1,2,3,3,3-heptafluoropropane and 49.5% 1,1,1,2-tetrafluoroethane. The patent application does not, however, disclose or suggest the use of ethanol as a component in combination with 1,1,1,2,3,3,3-heptafluoropropane.

European Patent Office Publication 0 384 371 (Heiskel) discloses solution aerosols in which 1,1,1,2,3,3,3-heptafluoropropane in combination with at least one of propane, butane, isobutane, dimethylether, and 1,1-difluoroethane serves as the propellant. The application does not, however, disclose suspension aerosols or pharmaceutical aerosol formulations.

Patent Application WO 91/02056 (Schultz et al.) describes suspension aerosol formulations comprising a medicinal agent, a member of a particular class of perfluorinated surface-active dispersing agent, and 1,1,1,2,3,3,3-heptafluoropropane. Albuterol sulfate is recited as a suitable medicinal agent. The patent application does not, however, teach or suggest the use of ethanol in combination with 1,1,1,2,3,3,3-heptafluoropropane.

SUMMARY OF THE INVENTION

This invention provides suspension aerosol formulations comprising a therapeutically effective amount of micronized albuterol sulfate and 1,1,1,2,3,3,3-heptafluoropropane as substantially the only propellant. This invention also provides suspension aerosol formulations comprising a therapeutically effective amount of micronized albuterol sulfate, from about 0.1 to about 15

percent by weight of ethanol, and 1,1,1,2,3,3,3-heptafluoropropane as substantially the only propellant.

This invention also provides suspension aerosol formulations comprising a therapeutically effective amount of micronized albuterol sulfate, from about 5 to 15 percent by weight of ethanol, from about 0.05 to about 0.5 percent by weight of a surfactant selected from the group consisting of oleic acid and sorbitan trioleate, and 1,1,1,2,3,3,3-heptafluoropropane as substantially the only propellant. This invention also provides a method for inducing bronchodilation in a mammal, comprising the step of administering to the mammal a formulation as described above by inhalation.

15 DETAILED DESCRIPTION OF THE INVENTION

All weight percentages recited herein are based on the total weight of the formulation unless otherwise indicated.

The term "suspension aerosol" means that the albuterol sulfate is in particulate form and the formulation is substantially free of dissolved albuterol sulfate.

The term "micronized" means that the albuterol sulfate is in the form of a fine powder, that is, over 90 percent of the particles will have a diameter of less than about 10 microns.

The formulations of the invention contain a therapeutically effective amount of micronized albuterol sulfate. Preferably micronized albuterol sulfate constitutes about 0.2 to about 0.5 percent by weight, more preferably from about 0.35 to about 0.42 percent by weight of the aerosol formulation.

Ethanol can optionally be included in a formulation of the invention. When ethanol is present it constitutes from about 0.1 to about 20 percent by weight, preferably from about 5 to about 15 percent by weight of the formulation. A surfactant selected from the group consisting of oleic acid and sorbitan trioleate can also optionally be included in the formulation when the

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.